Cannabis Suisse Corp. (CSUI) Aktienanalyse
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
CSUI steht fuer Cannabis Suisse Corp., ein Healthcare-Unternehmen mit einem Kurs von $ (Marktkapitalisierung 0). Bewertet mit 39/100 (vorsichtig) bei Wachstumspotenzial, finanzieller Gesundheit und Momentum.
Zuletzt analysiert: 16. März 2026Cannabis Suisse Corp. (CSUI) Gesundheitswesen & Pipeline-Uebersicht
Cannabis Suisse Corp. is a healthcare company focused on over-the-counter products, recreational tobacco, and medical CBD oils, distributed through its Swiss4Life brand and a retail network. With a high profit margin but negative gross margin, the company operates in a competitive and evolving market landscape.
Investmentthese
Cannabis Suisse Corp. presents a complex investment profile. While the company boasts a high profit margin of 1469.1%, its negative gross margin of -54.7% raises concerns about operational efficiency and cost management. The company's focus on over-the-counter products, recreational tobacco, and medical CBD oils positions it in a market with both growth potential and regulatory uncertainty. Key value drivers include the expansion of its Swiss4Life brand and the establishment of strategic retail partnerships. Upcoming regulatory changes in the cannabis industry could significantly impact the company's operations and profitability. Investors should closely monitor the company's ability to improve its gross margin and navigate the evolving regulatory landscape.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Profit Margin of 1469.1% indicates high profitability, but needs further investigation into the drivers and sustainability.
- Negative Gross Margin of -54.7% signals potential issues with cost of goods sold and pricing strategies.
- Market Cap of $0.00B indicates the company is a micro-cap stock with high volatility and risk.
- P/E Ratio of 7.70 suggests the stock may be undervalued compared to its earnings, but should be considered alongside other financial metrics.
- Beta of -4.65 indicates the stock is negatively correlated with the market, which may offer diversification benefits but also reflects unique company-specific risks.
Wettbewerber & Vergleichsunternehmen
Staerken
- Established Swiss4Life online retail brand.
- Diversified product line including cannabis-related and health-related products.
- Early mover advantage in the emerging cannabis market.
- High reported profit margin (though offset by negative gross margin).
Schwaechen
- Negative gross margin indicates potential issues with cost management.
- Limited market capitalization and potential liquidity concerns.
- Reliance on a relatively new and evolving regulatory landscape.
- Limited brand recognition compared to larger competitors.
Katalysatoren
- Ongoing: Expansion of the Swiss4Life brand through digital marketing and e-commerce initiatives.
- Ongoing: Strategic partnerships with major retailers to expand distribution network.
- Ongoing: Product diversification to include new and innovative health and wellness products.
- Upcoming: Potential changes in cannabis regulations that could create new market opportunities.
- Ongoing: Geographic expansion into new and emerging cannabis markets.
Risiken
- Ongoing: Intense competition from established pharmaceutical companies and emerging cannabis businesses.
- Ongoing: Evolving regulatory landscape and potential changes in cannabis laws.
- Potential: Fluctuations in commodity prices and supply chain disruptions.
- Potential: Negative public perception and potential health concerns related to cannabis and tobacco products.
- Ongoing: Negative gross margin indicating potential issues with cost management.
Wachstumschancen
- Expansion of Swiss4Life Brand: Cannabis Suisse Corp. can leverage its Swiss4Life brand to expand its online presence and direct-to-consumer sales. The global e-commerce market is projected to reach trillions of dollars in the coming years, offering a significant opportunity for growth. By investing in digital marketing and enhancing its online platform, the company can attract new customers and increase brand loyalty. Timeline: Ongoing.
- Strategic Retail Partnerships: Establishing partnerships with major retailers can significantly expand Cannabis Suisse Corp.'s distribution network and market reach. The retail industry is evolving, with consumers increasingly seeking health and wellness products in convenient locations. By securing shelf space in established retail chains, the company can increase product visibility and drive sales. Timeline: Ongoing.
- Product Diversification: Expanding the product line to include new and innovative health and wellness products can attract a broader customer base and increase revenue streams. The health and wellness market is constantly evolving, with new trends and consumer demands emerging regularly. By investing in research and development, Cannabis Suisse Corp. can create unique and differentiated products that meet the needs of its target market. Timeline: Ongoing.
- Geographic Expansion: Entering new geographic markets can significantly increase Cannabis Suisse Corp.'s growth potential. The global cannabis market is expanding rapidly, with new countries and regions legalizing cannabis for medical and recreational use. By carefully selecting target markets and adapting its products to local regulations and consumer preferences, the company can capitalize on this growth opportunity. Timeline: Upcoming.
- Regulatory Changes: Upcoming changes in cannabis regulations could create new opportunities for Cannabis Suisse Corp. As more jurisdictions legalize cannabis, the company can expand its operations and enter new markets. By staying informed about regulatory developments and adapting its business model accordingly, Cannabis Suisse Corp. can capitalize on these opportunities and gain a competitive advantage. Timeline: Ongoing.
Chancen
- Expansion of the Swiss4Life brand through digital marketing and e-commerce initiatives.
- Strategic partnerships with major retailers to expand distribution network.
- Product diversification to include new and innovative health and wellness products.
- Geographic expansion into new and emerging cannabis markets.
Risiken
- Increasing competition from established pharmaceutical companies and emerging cannabis businesses.
- Evolving regulatory landscape and potential changes in cannabis laws.
- Fluctuations in commodity prices and supply chain disruptions.
- Negative public perception and potential health concerns related to cannabis and tobacco products.
Wettbewerbsvorteile
- Established Swiss4Life online retail brand.
- Network of retail distribution partners.
- Diversified product line including cannabis-related and health-related products.
- Early mover advantage in the emerging cannabis market.
Ueber CSUI
Cannabis Suisse Corp., formerly Geant Corp., was established in 2016 and rebranded in February 2019 to reflect its focus on cannabis-related products. Headquartered in Bell Gardens, California, the company cultivates, produces, and distributes a range of products including over-the-counter health supplements, recreational tobacco products, and medical CBD oils. Its primary retail channel is Swiss4Life, an online brand, supplemented by a network of retailers. The product line extends beyond cannabis-related items to include health-related supplements, face masks, disinfectants, and traditional cigarettes. This diversified approach aims to capture a broader market segment within the health and wellness sector. The company's strategy involves leveraging both direct-to-consumer online sales and established retail partnerships to enhance market penetration and brand visibility. Cannabis Suisse Corp. operates within the evolving regulatory landscape of the cannabis industry, adapting its business model to comply with local and international laws.
Was das Unternehmen tut
- Cultivates and produces over-the-counter products.
- Manufactures and distributes recreational tobacco products.
- Produces and sells medical CBD oils.
- Sells products through the Swiss4Life online retail brand.
- Distributes products through a network of retailers.
- Offers health-related supplements.
- Provides face masks and disinfectants.
- Retails cigarettes.
Geschaeftsmodell
- Cultivation and production of cannabis-related products.
- Direct-to-consumer sales through the Swiss4Life online platform.
- Distribution through a network of retail partners.
- Sales of health-related supplements and other wellness products.
Branchenkontext
Cannabis Suisse Corp. operates within the specialty and generic drug manufacturing industry, a segment of the broader healthcare sector. The industry is characterized by intense competition, evolving regulatory landscapes, and increasing consumer demand for health and wellness products. Market trends include the growing acceptance of CBD products and the legalization of cannabis in various jurisdictions. Cannabis Suisse Corp. competes with established pharmaceutical companies and emerging cannabis businesses, navigating a complex environment of regulatory compliance and market differentiation. The company's success depends on its ability to innovate, adapt to changing regulations, and effectively market its products to a diverse consumer base.
Wichtige Kunden
- Consumers seeking over-the-counter health and wellness products.
- Individuals interested in recreational tobacco products.
- Patients seeking medical CBD oils for therapeutic purposes.
- Online shoppers through the Swiss4Life platform.
- Retail customers through the company's network of retail partners.
Finanzdaten
Chart & Info
Cannabis Suisse Corp. (CSUI) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
Keine aktuellen Nachrichten fuer CSUI verfuegbar.
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer CSUI.
Kursziele
Wall-Street-Kurszielanalyse fuer CSUI.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von CSUI auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Fuehrung: Scott W. Mcalister
CEO
Information on Scott W. Mcalister's background is not available in the provided context. Further research would be needed to determine his career history, education, and previous roles.
Erfolgsbilanz: Information on Scott W. Mcalister's track record is not available in the provided context. Further research would be needed to determine his key achievements, strategic decisions, and company milestones under his leadership.
CSUI OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the OTC market, indicating that Cannabis Suisse Corp. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, and trading activity can be sporadic. Investing in OTC Other stocks carries significant risks due to the lack of regulatory oversight and potential for fraud or manipulation. Investors should exercise extreme caution and conduct thorough due diligence before investing in companies on this tier.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited financial disclosure and transparency.
- Potential for fraud and manipulation.
- Low trading volume and liquidity.
- Wider bid-ask spreads and price volatility.
- Lack of regulatory oversight and investor protection.
- Verify the company's legal status and registration.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Understand the risks associated with the OTC market and the company's specific industry.
- Consult with a financial advisor before making any investment decisions.
- Company's operational history since 2016.
- Existence of a retail brand (Swiss4Life).
- Engagement in cultivation, production, and distribution activities.
- Physical headquarters in Bell Gardens, California.
Haeufige Fragen zu CSUI
What are the key factors to evaluate for CSUI?
Cannabis Suisse Corp. (CSUI) currently holds an AI score of 39/100, indicating low score. Key strength: Established Swiss4Life online retail brand.. Primary risk to monitor: Ongoing: Intense competition from established pharmaceutical companies and emerging cannabis businesses.. This is not financial advice.
How frequently does CSUI data refresh on this page?
CSUI prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven CSUI's recent stock price performance?
Recent price movement in Cannabis Suisse Corp. (CSUI) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Established Swiss4Life online retail brand.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider CSUI overvalued or undervalued right now?
Determining whether Cannabis Suisse Corp. (CSUI) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying CSUI?
Before investing in Cannabis Suisse Corp. (CSUI), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding CSUI to a portfolio?
Potential reasons to consider Cannabis Suisse Corp. (CSUI) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Established Swiss4Life online retail brand.. Additionally: Diversified product line including cannabis-related and health-related products.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of CSUI?
Yes, most major brokerages offer fractional shares of Cannabis Suisse Corp. (CSUI) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track CSUI's earnings and financial reports?
Cannabis Suisse Corp. (CSUI) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for CSUI earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Limited information available on CEO's background and track record.
- OTC market stocks are inherently riskier than exchange-listed stocks.